Cargando…

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens

BACKGROUND: The identification of baseline host determinants that associate with robust HIV-1 vaccine-induced immune responses could aid HIV-1 vaccine development. We aimed to assess both the collective and relative performance of baseline characteristics in classifying individual participants in ni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunda, Zhang, Yuanyuan, Seaton, Kelly E., De Rosa, Stephen, Heptinstall, Jack, Carpp, Lindsay N., Randhawa, April Kaur, McKinnon, Lyle R., McLaren, Paul, Viegas, Edna, Gray, Glenda E., Churchyard, Gavin, Buchbinder, Susan P., Edupuganti, Srilatha, Bekker, Linda-Gail, Keefer, Michael C., Hosseinipour, Mina C., Goepfert, Paul A., Cohen, Kristen W., Williamson, Brian D., McElrath, M. Juliana, Tomaras, Georgia D., Thakar, Juilee, Kobie, James J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520208/ https://www.ncbi.nlm.nih.gov/pubmed/36179551 http://dx.doi.org/10.1016/j.ebiom.2022.104271

Ejemplares similares

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
por: Fisher, Leigh, et al.
Publicado: (2019)

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
por: Stieh, Daniel J, et al.
Publicado: (2022)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
por: Baden, Lindsey R, et al.
Publicado: (2020)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

Vaccination establishes clonal relatives of germinal center T cells in the blood of humans
por: Heit, Antje, et al.
Publicado: (2017)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Vaccination with MVA/HIV induces differential recruitment of monocyte subsets into the circulation and monocyte-specific transcriptional programs
por: Andersen-Nissen, E, et al.
Publicado: (2012)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load
por: Janes, Holly, et al.
Publicado: (2012)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa
por: Bekker, Linda-Gail, et al.
Publicado: (2020)

Emergent Electroweak Gravity
por: McElrath, Bob
Publicado: (2008)

Laboratory tests for the cosmic neutrino background using beta-decaying nuclei
por: McElrath, Bob
Publicado: (2009)

On The Origin of Neutrino Mass and Mixing in the Standard Model
por: McElrath, Bob
Publicado: (2009)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
por: Mayer-Blackwell, Koshlan, et al.
Publicado: (2022)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

$h \to \mu^{+}\mu^{-}$ via Gluon Fusion at the LHC
por: Han, T, et al.
Publicado: (2002)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012)

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans
por: Xu, Shiwei, et al.
Publicado: (2022)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
por: Zhao, Lue Ping, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p0ic1fjoua338regbf9id5839s